How to Change Your Ability to Change

The monoamine hypothesis of depression leaves many patients without effective help. It’s time for a paradigm shift, and psychedelics may be leading the way.

-

Until recently, the story of depression went something like this: Due to a complex interplay of factors, including stress and genetics and other imperfectly understood things, the brain lacks enough monoamine neurotransmitters – particularly serotonin. Treatment, therefore, means replacing the missing neurotransmitters with specialized drugs that increase the brain’s serotonin levels. 

That works persistently well – for about 12% of patients.1 And for some doubly unlucky people, antidepressants may be even worse than a placebo.2 Sometimes, scientific stories are missing a few chapters.

Disorders of Rigidity

Rather than a simple serotonin deficiency, depression can also be seen as a disorder of rigidity. 

It traps people in negative thinking. Depressed patients tend to interpret ambiguous information negatively,3 and because life is often ambiguous, this has disastrous results. Patients develop a decidedly negative self-image, pessimistic expectations for the future, and a sense of hopelessness that is difficult to shake.4 

Although it is difficult to directly relate mental states with biological events, scientists see a potential connection between cognitive rigidity and a kind of biological rigidity, specifically reductions in neuroplasticity. Neuroplasticity, roughly speaking, is the brain’s ability to form new connections and adapt to the constant changes in the world around it.5 Depressed brains suffer from a pronounced lack of neuroplasticity, particularly in regions relevant for mood regulation and self image5,6. Neurons atrophy and send out fewer dendritic spines to connect with their neighbors, and the brain produces fewer growth factors that stimulate neuroplasticity. This sometimes begins with chronic stress, although other triggers certainly exist.7 The resulting lack of biological flexibility may be one reason depressive disorders are so hard to break free from.

How to Change Your Ability to Change

If impaired neuroplasticity is an important part of depression’s pathophysiology, it stands to reason that stimulating plasticity could reduce symptoms.6 Antidepressants seem to stimulate neuroplasticity to some extent, but they must be taken chronically, cause objectionable side effects, and take two weeks to work at all.5 Thus, some scientists are looking to other plasticity-stimulating molecules: those that work well, work quickly, and work after being taken only once. Since 2018, they have a name: the psychoplastogens.5

Many psychoplastogens are psychedelics, and indeed, most psychedelics stimulate neuroplasticity.8 Ketamine, which also rapidly reduces depressive symptoms, is also in this class, as are several molecules with no psychoactive effects at all.8 Psychoplastogens are all characterized by their ability to cross into the brain and rapidly stimulate neuroplasticity, and those that are the most useful do this only in particular circuits and brain regions.5 Most importantly, changes in neuroplasticity seem to stick around: Ketamine’s antidepressant effects last for 1-2 weeks,9 while in clinical trials with psilocybin, patients seem to need treatment anywhere between once a month and just once, period.10,11

Lightspring / Shutterstock

This theory also has an essential second chapter: psychoplastogens are best combined with psychotherapy.12 There is still no magic pill that can cure depression. Instead, these drugs may open up a “window of plasticity” during which the brain – the patient, really – is more responsive to therapy.13 Enhanced neuroplasticity alone is not automatically good; it has to happen in the right neural circuits and, ideally, be paired with therapeutically helpful experiences.5,14 Therapy and other supportive activities give the newly plastic brain a positive direction in which to change.

Theory Means “A Work in Progress”

The neuroplasticity theory may explain a lot, but all theories are works in progress. So far, scientists have found evidence that psychedelics stimulate several important elements of neuroplasticity in rodents, and they have reason to conclude that this could also happen in humans.5,8 But just as depression isn’t reducible to “too little serotonin,” it is also not simply caused by “too little plasticity.” Psychiatry is moving away from such reductionist views.

It also isn’t clear yet whether impaired neuroplasticity in certain neural circuits directly causes depression, or whether stimulating plasticity is truly a reason that psychedelic therapy works in humans, as opposed to other aspects of the subjective psychedelic experience and its underlying biology. And human research still suffers from “technical difficulties”: measuring neuroplasticity in the lab involves slicing brains up or putting them through what is essentially a professional blender. Although scientists can measure proxies of neuroplasticity without turning anyone’s brain into a smoothie, the resulting data can be hard to interpret. This means that we have little direct evidence of psychedelics stimulating neuroplasticity in humans. 

But although the unknown can disappoint, it is also promising. Psychedelics also seem to treat anxiety, addictions, and PTSD in addition to depression,15,16 and researchers are also interested in obsessive-compulsive disorder, eating disorders,17 and even personality disorders.18,19 Could these also be “disorders of rigidity”? Psychologists have long wondered if a general pathology underlies seemingly distinct mental health problems, especially because many of these disorders tend to occur together. While one could rightly criticize this idea as too simple, pursuing it in research may nevertheless bring science closer to the more complex truth. Perhaps impaired neuroplasticity isn’t the cause of all of these disorders, but it may be standing in the way when people try to get better.

The Take-Home Message

A new story of depression goes like this: at some point in a patient’s life, the brain’s natural ability to adapt begins to atrophy. This loss of neuroplasticity may happen in circuits that regulate mood, and once they are impaired, the brain ends up “stuck” in a depressive disorder. Restoring neuroplasticity could reopen the highway to health. 

As with many theories, this one is attractive because it explains an initially mysterious observation. Ketamine, psychedelics, and other psychoplastogens seem to be astonishingly effective at treating depression, and likely other disorders as well. The neuroplasticity theory of drugs and depression elegantly explains why. If it stands the test of time and science, this theory could lead to more breakthroughs in research on mental health and beyond.

2 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Alex Baradoy
2 days ago

Best article ive read in a long time
Glad i found this site.
Keep up the good work

Anonymous
19 hours ago

That would be great. Obviously, we don’t want to just start dosing people down for every little thing, but I think this is promising, based on my own experiences throughout my life. I have dosed heavily on LSD and mushrooms a hundred times or more and hadn’t really made the connection that it was more-than-likely what had kept me from the deep, manic depression that I had fallen into during my divorce. Once I was at that point, I did feel that my forward progress in life was done, which led to further regression, depression and I lost, not only… Read more »

    References
  1. Price RB, Duman R. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Mol Psychiatry. 2020;25(3):530-543. doi:10.1038/s41380-019-0615-x
  2. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry. 2011;68(12):1227-1237. doi:10.1001/archgenpsychiatry.2011.132
  3. Hollon SD, Beck AT. Cognitive Therapy of Depression. Cognitive-Behavioral Interventions. Published online 1979:153-203. doi:10.1016/b978-0-12-404480-7.50012-5
  4. Hasler G, Suker S, Schoretsanitis G, Mihov Y. Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study. Frontiers in Neuroscience. 2020;14. doi:10.3389/fnins.2020.00687
  5. Olson DE. Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508. doi:10.1177/1179069518800508
  6. Huang Y-J, Lane H-Y, Lin C-H. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. Neural Plast. 2017;2017:4605971. doi:10.1155/2017/4605971
  7. Boku S, Nakagawa S, Toda H, Hishimoto A. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry and Clinical Neurosciences. 2018;72(1):3-12. doi:10.1111/pcn.12604
  8. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
  9. Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019;101(5):774-778. doi:10.1016/j.neuron.2019.02.005
  10. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry. Published online 2020. doi:10.1001/jamapsychiatry.2020.3285
  11. Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders. 2019;258:11-24. doi:10.1016/j.jad.2019.07.076
  12. Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry. 2018;30(4):291-316. doi:10.1080/09540261.2018.1486289
  13. Hasler G. Toward specific ways to combine ketamine and psychotherapy in treating depression. CNS Spectr. 2020;25(3):445-447. doi:10.1017/S1092852919001007
  14. Mishra J, Gazzaley A. Harnessing the neuroplastic potential of the human brain & the future of cognitive rehabilitation. Frontiers in Human Neuroscience. 2014;8. doi:10.3389/fnhum.2014.00218
  15. Winkelman M. Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca. Current Drug Abuse Reviews. 2015;7(2):101-116. doi:10.2174/1874473708666150107120011
  16. Luoma JB, Chwyl C, Bathje G, Davis AK, Lancelotta R. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. doi:10.31234/osf.io/nhbjk
  17. Spriggs MJ, Kettner H, Carhart-Harris RL.Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. Published online 2020. doi:10.1007/s40519-020-01000-8
  18. Müller F, Mühlhauser M, Holze F, et al. Treatment of a Complex Personality Disorder Using Repeated Doses of LSD—A Case Report on Significant Improvements in the Absence of Acute Drug Effects. Frontiers in Psychiatry. 2020;11. doi:10.3389/fpsyt.2020.573953
  19. Zeifman RJ, Wagner AC. Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. Journal of Contextual Behavioral Science. 2020;15:1-11. doi:10.1016/j.jcbs.2019.11.001